Report

Hemorrhoid Treatment Devices Market Analysis

The hemorrhoid treatment devices market size in 2026 is estimated at USD 1.28 billion, growing from 2025 value of USD 1.21 billion with 2031 projections showing USD 1.67 billion, growing at 5.54% CAGR over 2026-2031. Growth is fueled by aging populations, a global shift toward outpatient care, and the rapid adoption of minimally invasive technologies that shorten recovery times and lower overall treatment costs. AI-guided endoscopy, Doppler-guided ligation, and laser hemorrhoidoplasty are widening the therapeutic toolbox, allowing physicians to intervene earlier, reduce postoperative pain, and improve long-term outcomes. Healthcare payers are increasingly reimbursing outpatient procedures, so providers are prioritizing ambulatory surgical centers that can deliver standardized, high-volume treatments at a lower cost without compromising safety or efficacy. Meanwhile, established manufacturers are focusing on technology differentiation, sustainability, and single-use designs that align with infection-control policies and environmental directives.

Global Hemorrhoid Treatment Devices Market Trends and Insights



Rising Prevalence of Symptomatic Hemorrhoids

Nearly 10 million Americans were affected by symptomatic hemorrhoids in 2024, representing about 5% of the adult population. The incidence rate rises sharply after age 50, ensuring a sustained patient pool as the population ages demographically. Sedentary work patterns, high-fat diets, and increasing obesity intensify symptom severity, especially in urban centers where advanced treatment is readily accessible. As emerging economies age and adopt similar lifestyles, epidemiological curves in those regions are expected to track those of developed markets. Together, these factors underpin a broad and predictable demand base that supports continued expansion of the hemorrhoid treatment devices market

Preference for Minimally Invasive Outpatient Procedures

Patients and payers alike prefer procedures that shorten recovery and avoid overnight admission. Medicare reimburses key hemorrhoid ligation codes, making outpatient treatment financially attractive for providers. Laser hemorrhoidoplasty patients in a 2024 case series reported no pain or bleeding by day 4, highlighting a faster convalescence compared to open surgery. Ambulatory surgical centers, which combine specialized staff with high-throughput workflows, are capturing a growing share of the volume. Collectively, these trends accelerate migration away from inpatient settings and reinforce steady demand for advanced devices.

Limited Reimbursement in Developing Markets

In many emerging economies, insurance budgets prioritize communicable diseases and maternal health, so hemorrhoid interventions are often paid out-of-pocket. The high ticket price of Doppler-guided or laser systems places them out of reach for lower-income patients, leading to a two-tiered market where affluent urban citizens access advanced care while rural populations rely on conservative management. This gap dampens overall installed-base growth, slows training uptake among clinicians, and tempers the long-run CAGR of the hemorrhoid treatment devices market.

Other drivers and restraints analyzed in the detailed report include:

Technological AdvancesHealthcare Expenditure Growth in Asia-PacificOTC Topical Products Delaying Device Adoption

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Rubber band ligators remained the leader, accounting for 41.98% of the 2025 hemorrhoid treatment devices market share, reflecting decades of clinical familiarity, low unit costs, and minimal capital requirements. Doppler-guided ligation systems, however, are on a faster growth trajectory, posting a 6.28% CAGR to 2031 as surgeons migrate to real-time vessel localization, which curbs recurrence. The THD Revolution platform exemplifies this shift with integrated imaging, intuitive controls, and sterility-optimized accessories. Infrared coagulators and sclerotherapy injectors maintain relevance for grades I and II disease, where tissue sparing is paramount. Bipolar probes supply targeted thermal energy for select patient groups, whereas cryotherapy devices find niche application in districts where disposables remain cost-prohibitive. As sustainability regulations tighten, producers are exploring biopolymer housings and single-use kits that strike a balance between infection control and environmental impact. Such design innovations are expected to preserve the value proposition of entry-level ligators while nudging the category into higher-margin territory.

The Hemorrhoid Treatment Devices Market is Segmented by Product Type (Band Ligators, Bipolar Probes, Laser Probes, Cryotherapy Devices, Infrared Coagulators, Sclerotherapy Injectors, and Others), and Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Value is Provided in (USD Million) for the Above Segments.

Geography Analysis

North America held the leading 41.86% revenue share in 2025, supported by Medicare coverage for CPT codes 46221, 46945, and 46946, which pay providers an average of USD 400 per procedure. Strong hospital infrastructure, widespread availability of high-definition endoscopes, and expedited FDA pathways for Class II ligators underpin the region's dominance.

The Asia-Pacific region is the fastest-growing geography, with a 6.12% CAGR forecasted to 2031. China streamlined its device registration framework in 2024, reducing average review cycles and enhancing post-market surveillance, which in turn boosts both foreign and domestic investment. India's marketing conduct code formalized promotional standards, rewarding multinational producers that maintain rigorous compliance. Olympus recorded 32% year-over-year gains in North America, while reporting strong therapeutic endoscopy demand in Asia, confirming the cross-regional transferability of GI platforms. Urbanizing populations, rising disposable income, and heightened health awareness combine to create sustained momentum for advanced hemorrhoid interventions.

Europe represents a mature yet resilient market. Strict infection-control mandates and environmental directives encourage single-use device adoption, pushing manufacturers to redesign ligators with recyclable bio-polymers. Reimbursement structures vary, yet most national payers now cover Doppler-guided procedures for higher-grade disease, underpinning steady replacement cycles. South America and the Middle East & Africa remain emerging segments: limited reimbursement and fewer trained proctologists cap uptake outside major cities, although rising employer-sponsored insurance and public-sector infrastructure projects are gradually widening access to device-based care.

List of Companies Covered in this Report:

Boston Scientific Medtronic Johnson�&�Johnson Cook Group Olympus Teleflex Conmed CooperSurgical (Wallace) A.M.I. Agency for Medical Innovations Lohmann & Rauscher Sklar Surgical Instruments Sterylab Privi Medical The Cooper Companies Integra LifeSciences Smiths Group Hologic

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support